Brookstone Capital Management’s Quest Diagnostics DGX Stock Holding History

Brookstone Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$275K	Sell	1,297 -654	-34%	-$128K	﹤0.01%	1137
2026 Q1	$382K	Buy	1,951 +668	+52%	+$130K	﹤0.01%	959
2025 Q4	$223K	Sell	1,283 -262	-17%	-$47.7K	﹤0.01%	1084
2025 Q3	$295K	Sell	1,545 -1,419	-48%	-$252K	﹤0.01%	980
2025 Q2	$532K	Buy	2,964 +163	+6%	+$28.3K	0.01%	727
2025 Q1	$474K	Sell	2,801 -916	-25%	-$150K	0.01%	728
2024 Q4	$561K	Buy	3,717 +1,439	+63%	+$224K	0.01%	659
2024 Q3	$354K	Sell	2,278 -99	-4%	-$14.8K	0.01%	785
2024 Q2	$353K	Buy	+2,377	New	+$326K	0.01%	743
2023 Q1	–	Sell	-1,400	Closed	-$218K	–	842
2022 Q4	$218K	Buy	+1,400	New	+$201K	﹤0.01%	763
2022 Q2	–	Sell	-1,479	Closed	-$203K	–	773
2022 Q1	$203K	Sell	1,479 -1,777	-55%	-$248K	﹤0.01%	736
2021 Q4	$507K	Sell	3,256 -272	-8%	-$41.4K	0.01%	523
2021 Q3	$497K	Sell	3,528 -685	-16%	-$100K	0.01%	501
2021 Q2	$569K	Buy	4,213 +2,603	+162%	+$341K	0.01%	458
2021 Q1	$207K	Buy	+1,610	New	+$198K	0.01%	467
2015 Q4	–	Sell	-200	Closed	-$12K	–	324
2015 Q3	$12K	Sell	200 -200	-50%	-$14K	﹤0.01%	1024
2015 Q2	$29K	Buy	+400	New	+$29.5K	﹤0.01%	679

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Brookstone Capital Management's DGX Position: Q2 2026 in Review

Brookstone Capital Management reduced its Quest Diagnostics (DGX) stake by 34% in Q2 2026, selling an estimated $128K and leaving 1,297 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Brookstone Capital Management first reported a position in DGX in Q2 2015 and has held it in 17 quarters since. The position peaked at $569K in Q2 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Brookstone Capital Management held 1,297 shares of Quest Diagnostics worth $275K as of Q2 2026.
Brookstone Capital Management sold 654 Quest Diagnostics shares in Q2 2026, an estimated $128K.
Quest Diagnostics made up ﹤0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #1137 holding.
Brookstone Capital Management first reported a position in Quest Diagnostics in Q2 2015 and has held it in 17 quarters since.
Brookstone Capital Management's Quest Diagnostics position peaked at $569K in Q2 2021.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.